Activist Investor Demands Governance Reset and Cash Preservation at Capricor
CAPR has more than doubled off its 52-week low of $2.96.
Summary
Kaos Capital Ltd. sent a formal letter to Capricor's board demanding immediate governance changes, aggressive cash preservation, and a strategic realignment away from sole reliance on deramiocel. The activist plans to nominate two independent directors and push for an M&A and Strategic Alternatives Committee. Kaos highlights that cash fell $80.2M from year-end 2025 to $237.9M as of June 30, 2026, with H1 operating expenses of $79.7M and G&A roughly doubling to $23.5M. This follows the FDA advisory committee's 9-3 vote against deramiocel's effectiveness data on July 30 and the subsequent 118% premarket surge on August 14 after the FDA agreed to review new 24-month data. The stock fell 8.92% to $6.22 on Friday. The activist pressure adds a new governance and capital allocation overhang ahead of the August 22 PDUFA decision for deramiocel.
At the time of this announcement, CAPR was trading at $6.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355.8M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.